TPO and myelodysplastic syndrome: Concerning thrombopoietin-receptor agonists (TPO-RA), insufficient agreement was found on the type of agent, the threshold (tendency <20 G/L) and the appropriate indication in MDS patients (tendency for lower-risk MDS, concomitant ITP and hypoplastic MDS).